Our findings were consistent with a comprehensive meta-analysis of seven prospective studies involving 31,545 individuals, which reported that for every 5 U/L rise in ALT levels, the relative risk (RR) of incident MetS increased by 13% in males and 38% in females (gender difference P-value = 0.007) (16). This evidence concerns the gene GPT and metabolic syndrome.